These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36867282)

  • 1. Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer.
    Dix-Peek T; Phakathi BP; van den Berg EJ; Dickens C; Augustine TN; Cubasch H; Neugut AI; Jacobson JS; Joffe M; Ruff P; Duarte RAB
    Breast Cancer Res Treat; 2023 May; 199(1):1-12. PubMed ID: 36867282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
    Lopez-Tarruella S; Del Monte-Millán M; Roche-Molina M; Jerez Y; Echavarria Diaz-Guardamino I; Herrero López B; Gamez Casado S; Marquez-Rodas I; Alvarez E; Cebollero M; Massarrah T; Ocaña I; Arias A; García-Sáenz JÁ; Moreno Anton F; Olier Garate C; Moreno Muñoz D; Marrupe D; Lara Álvarez MÁ; Enrech S; Bueno Muiño C; Martín M
    Breast Cancer Res Treat; 2024 Jan; 203(1):163-172. PubMed ID: 37773555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
    Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
    Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
    Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
    BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
    Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B.
    Raj-Kumar PK; Liu J; Hooke JA; Kovatich AJ; Kvecher L; Shriver CD; Hu H
    Sci Rep; 2019 May; 9(1):7956. PubMed ID: 31138829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
    Sánchez-Muñoz A; Vicioso L; Santonja A; Álvarez M; Plata-Fernández Y; Miramón J; Zarcos I; Ramírez-Tortosa CL; Montes-Torres J; Jerez JM; de Luque V; Llácer C; Fernández-De Sousa CE; Pérez-Villa L; Alba E
    Mod Pathol; 2018 Feb; 31(2):299-306. PubMed ID: 28984296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining breast cancer intrinsic subtypes by quantitative receptor expression.
    Cheang MC; Martin M; Nielsen TO; Prat A; Voduc D; Rodriguez-Lescure A; Ruiz A; Chia S; Shepherd L; Ruiz-Borrego M; Calvo L; Alba E; Carrasco E; Caballero R; Tu D; Pritchard KI; Levine MN; Bramwell VH; Parker J; Bernard PS; Ellis MJ; Perou CM; Di Leo A; Carey LA
    Oncologist; 2015 May; 20(5):474-82. PubMed ID: 25908555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
    Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
    Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Badr NM; Zaakouk M; Zhang Q; Kearns D; Kong A; Shaaban AM
    Histopathology; 2024 Sep; 85(3):437-450. PubMed ID: 38651302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
    Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
    BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
    Wirtz RM; Sihto H; Isola J; Heikkilä P; Kellokumpu-Lehtinen PL; Auvinen P; Turpeenniemi-Hujanen T; Jyrkkiö S; Lakis S; Schlombs K; Laible M; Weber S; Eidt S; Sahin U; Joensuu H
    Breast Cancer Res Treat; 2016 Jun; 157(3):437-46. PubMed ID: 27220750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
    Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
    Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
    Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer molecular subtypes and receptor status among women at Potchefstroom Hospital: a cross-sectional study.
    Kakudji BK; Mwila PK; Burger JR; du Plessis JM; Naidu K
    Pan Afr Med J; 2021; 38():85. PubMed ID: 33889251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
    Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
    Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular subtyping of male breast cancer by immunohistochemistry.
    Kornegoor R; Verschuur-Maes AH; Buerger H; Hogenes MC; de Bruin PC; Oudejans JJ; van der Groep P; Hinrichs B; van Diest PJ
    Mod Pathol; 2012 Mar; 25(3):398-404. PubMed ID: 22056953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.